icad (ICAD) Total Current Assets : $29.68 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is icad Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. icad's total current assets for the quarter that ended in Dec. 2023 was $29.68 Mil.

icad Total Current Assets Historical Data

The historical data trend for icad's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

icad Total Current Assets Chart

icad Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

29.20

42.30

50.31

38.24

29.68

icad Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															38.24	34.20	31.34	32.34	29.68

icad Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

icad's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	21.67	+	6.392	+	0.917	+	0.699
	=	29.68

icad's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	21.67	+	6.392	+	0.917	+	0.699
	=	29.68

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

icad (NAS:ICAD) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

icad's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	21.67	-	8.001	+	0.75 * 6.392	+	0.5 * 0.917
=	18.92

icad Total Current Assets Related Terms

Thank you for viewing the detailed overview of icad's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

icad (ICAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062

Website

https://www.icadmed.com

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

Executives

Eric Lonnqvist	officer: See Remarks	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea	officer: See Remarks	2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go	officer: Sr. VP of R&D	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno	officer: See Remarks	C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine	director	82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton	director	C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood	director	845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein	director	C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter	officer: See Remarks	C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens	officer: Executive VP of Marketing	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado	officer: Interim Chief FinancialOfficer	98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel	director	15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard	director	C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831